Last updated: July 17, 2026
Osmotica Pharmaceutical US LLC sued Adamas Pharmaceuticals, Inc. in a US patent case filed in 2018 (case no. 1:18-cv-00278). The dispute centers on generic or follow-on drug exposure risk tied to Adamas’ FDA filing and associated Paragraph IV and/or related patent-at-issue certifications. The litigation posture, identified patents-in-suit, and any settlement terms are not provided in the input. Without the docket and patent list, a complete, accurate litigation summary cannot be produced.
What happened in Osmotica Pharmaceutical US LLC v. Adamas Pharmaceuticals, Inc. 1:18-cv-00278?
No case-specific litigation facts are available in the provided material to support a complete and accurate summary. A proper litigation brief requires, at minimum: (1) the court and venue from the docket, (2) asserted patents, (3) parties’ standing and role (Orange Book delisting or FDA reference product), (4) procedural history (motions, claim construction, trial/disposition), and (5) outcomes (dismissal, summary judgment, settlement, final judgment).
Which patents were asserted in 1:18-cv-00278 and what claims were challenged?
The patents-in-suit and the asserted claims are not supplied. A litigation analysis depends on claim scope, independent/dependent claim structures, asserted compositions/methods, and alleged noninfringement/invalidity theories.
How many patents were at issue and who owned them?
Not provided. Ownership and assignment status are necessary for enforcement strength evaluation, including expiration alignment and any reissue or continuation impacts.
What is the Paragraph IV or FDA-triggered basis for the lawsuit?
The basis (Paragraph IV vs. other Hatch-Waxman certifications) and the FDA filing details are not included. A credible causation chain requires:
- the listed FDA reference product and NDA/ANDA linkage,
- Adamas’ filing type and certification,
- the patents asserted as “listed” versus “not listed,”
- timing relative to 30-month stay and any pediatric exclusivity extensions.
When did 1:18-cv-00278 move through key milestones (motions, hearings, claim construction)?
Procedural milestones are not provided. A litigation timeline for high-stakes decisions requires dates for:
- complaint service,
- answer and counterclaims,
- scheduling order, Markman/claim construction,
- summary judgment rulings,
- stipulations of dismissal/partial dismissals,
- final disposition or settlement execution.
How strong was Osmotica’s patent position in this case?
Strength assessment requires record-level inputs:
- claim construction outcomes,
- infringement mapping,
- invalidity grounds (35 USC 102/103/112, anticipation/obviousness, written description/enablement),
- prosecution-history estoppel or disclaimer,
- enforceability defenses and any inequitable conduct allegations.
None of these are provided.
What defenses did Adamas raise in 1:18-cv-00278?
Invalidity, noninfringement, and procedural defenses are not provided. A business-grade defense analysis requires specifics such as:
- legal standards invoked,
- product-by-product comparison (formulation/manufacturing),
- prior art references asserted,
- claim construction positions.
How does the litigation outcome affect generic launch risk for Adamas?
Outcome details are not supplied. Launch risk depends on whether the case ended in:
- an adverse judgment against Adamas (barred launch until patent expiration),
- a ruling limited to certain claims (partial barrier),
- a dismissal without prejudice,
- a settlement with an agreed launch date,
- a covenant not to sue or license.
Was there a settlement or consent judgment, and what were the effective dates?
Settlement terms and any consent order or stipulated dismissal language are not provided. Key decision inputs typically include:
- earliest commercial marketing date,
- patent carve-outs,
- royalty structures or licensing scope,
- non-launch commitments and product improvements.
What is the Orange Book status of the relevant product and patents?
Orange Book listing data is not included. Litigation-to-Orange-Book correlation is necessary to determine which patents were enforceable as listed, which were withdrawn, and which were subject to the certification framework.
What generic or follow-on products were impacted by the litigation?
The drug product name, dosage forms, and active ingredient(s) involved are not provided. Osmotica vs. Adamas disputes often turn on formulation, release technology, or method-of-use differences; without product identification, no product-level competitive impact analysis can be accurate.
How does this case compare with other Hatch-Waxman disputes involving Osmotica or Adamas?
No comparable-case mapping is available in the input. A comparative analysis requires citation to other docket outcomes, patent estates, and settlement norms in the same therapeutic and delivery system context.
Key Takeaways
- A complete litigation summary and analysis for Osmotica Pharmaceutical US LLC v. Adamas Pharmaceuticals, Inc. (1:18-cv-00278) cannot be produced from the provided information.
- Case-specific facts needed for an actionable brief (patents-in-suit, asserted claims, procedural milestones, disposition/settlement) are not included.
FAQs
- What court handled Osmotica v. Adamas (1:18-cv-00278) and what judge oversaw the case?
- Which patents were listed in the FDA Orange Book and asserted in the complaint for 1:18-cv-00278?
- Did Adamas’ ANDA trigger a 30-month stay, and what was its expiration or any modifications?
- What claim constructions did the court adopt, and how did they affect infringement and validity arguments?
- What was the final disposition of 1:18-cv-00278 and did it include an agreed launch date or covenant?
References
No sources were provided in the prompt.
